() was elevated 11% to 0.355p after it gave an update on funding.
The property management and long-dated income specialist is in advanced stages of talks with financial institutions with regards to the funding it is looking to raise for the gas peaking projects first announced via its joint venture with HSKB in March 2021.
The terms that have been offered since the recent general meeting of the company’s shareholders have been significantly better than those previously offered or available prior to the previous funding announcement, Dukemount revealed.
1.45pm: Investors like a Flutter
() had many investors taking a punt on the shares after it higher pro-forma first-half revenue of £3.1bn, up 30% year-on-year, as the sporting calendar normalised.
Customer volumes were similarly higher, with average monthly players up 40% over the six months compared to last year.
"The first half of 2021 exceeded our expectations,” said chief executive Peter Jackson. “Our global sports businesses benefitted from further enhancements to our products and the return to more normalised sporting calendars while we sustained our strong performance in gaming despite the challenging comparatives set last year.”
The shares were up 9.4% at 14,150p.
12.50pm: Fusion Antibodies tumbles after posting wider losses
() tumbled 7% to 125p in the early afternoon after posting an increase in yearly losses to £2.9mln from £700,000 compared to the year ended in March 2020.
The pre-clinical antibody group, which nonetheless saw revenue rising 7% to £4.2mln, said it was due to investment in operations and research.
Post-year-end trading has been in line with expectations, although the AIM-listed firm noted there is still “considerable uncertainty” as its markets are grappling with COVID-19.
12.25pm: MaxCyte grants options after announcing licensing deal yesterday
(, ) headed 5.8% higher to 1,100p after it granted a pile of options over 100,000 shares (in aggregate) to directors and officers of the company.
The options have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 9 August 2021, of US$16.63.
The awards follow yesterday’s announcement of a licensing agreement with Sana Biotechnology, which will have non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and programme-related milestone payments.
10.55am: S&U trading ahead of expectations
(, ) rose 4.0% to 2,933.5p after it said trading was currently ahead of expectations “in terms of profitability, collections and book debt quality”.
Updating investors, the finance specialist said its Advantage motor operation continued to enjoy a “profitable, controlled and cash generative recovery”.
It added that new business was gradually increasing, “month by month, to nearer normal levels”.
10.00am: River and Mercantile responds to press speculation
() PLC saw its shares rise 7.1% to 225p in the wake of press comment.
The company has confirmed it has received a number of approaches from external parties expressing interest in acquiring its Solutions business.
Discussions are at an early stage and there is no assurance that a transaction will arise, the company advised.
9.05am: Botswana Diamonds higher after latest diamonds find
() climbed 5% to 1.1p after it revealed diamonds have been recovered from the River Kimberlite extension at Thorny River in the Limpopo province of South Africa.
Four diamonds “of good colour and clarity” were recovered, the company said.
A new drilling programme is scheduled to begin at the site by the end of August.
() was the top riser on Tuesday morning with a gain of 36% at 5.32p after the software company confirmed it has received a bid approach.
The approach is from Science Group, which acquired a 10.2% stake in TP Group on Monday at a price of 5p per share, and is preliminary in nature. TP Group gave the usual get-out causes about there being no certainty a bid will materialise.
Science Group said it has repeatedly sought to engage with the board of TP Group in recent months with regard to exploring a strategic investment and more recently in relation to a potential combination of the two companies. These informal and formal approaches have all been rejected, without any discussion, by the TP Group board, Science Group said.